Considering the low incidence rates of primary sebaceous carcinoma (SC) of extraorbital sites, let alone those occur in intraoral sites, clinicopathological characteristics and histogenesis are not fully understood. In the present case, a maxillary mass was presented and a low-grade malignant tumor was suspected according to the CT scans, preoperative FNA, and clinical conditions. Other carcinomas, including acinar cell carcinoma (ACC), basaloid cell carcinoma (BCC), SCC, mucoepidermoid carcinoma, and epithelial-myoepithelial carcinoma (EMC), were also considered before surgery. Due to the rare occurrence of SC and no preoperative suspects, a fresh sample was not kept. Sadly, thus cause those special stains (e.g., Oil Red O and Sudan IV) which form the primary basis for a diagnosis of SC in academic circles were missing. A comprehensive literature review identified only 10 cases of intraoral SC, of which the primary sites reported in the English literature were the buccal mucosa, mouth floor, upper labial mucosa, and tongue. Due to an absence of specific biomarkers and simulated characters, histochemistry and immunohistochemistry such as PAS, CK, EMA, p63, p53, S-100, calponin, CD117, Ki-67, a-SMA, and AR form the diagnostic standard of SC. Postoperative immunohistochemistry of our case showed S100(-), Ki-67(-), calponin(-), CD117(-), CK20(-), PAS(-), AR(+), CK(+), CK5/6(+), P53(+), P63(+), a-SMA (+). Thus the diagnosis of SC was finally made. Through discussing the findings of our case and reviewing literature, we present the histological features and discuss possible outstanding biomarkers of this neoplasm.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8184391 | PMC |
http://dx.doi.org/10.21037/gs-21-218 | DOI Listing |
Arch Dermatol Res
January 2025
Oncologic Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, 40126, Italy.
Invest Ophthalmol Vis Sci
January 2025
Department of Ophthalmology, Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Purpose: To evaluate the prognosis of eyelid sebaceous carcinoma (SeC) in patients with disease stage worse than IIA.
Methods: This retrospective, single-center study included 78 SeC patients. For stage II patients, 1:3 propensity score matching (PSM) was applied between those undergoing orbital exenteration and those receiving eye-sparing treatments.
Int J Dermatol
January 2025
Division of Dermatology, Department of Medicine, Houston Methodist Hospital, Houston, Texas, USA.
Head Neck Pathol
January 2025
Department of Pathology, University Medical Center Utrecht, Utrecht, 3508 GA, The Netherlands.
Purpose: The NAB2::STAT6 fusion is predominantly associated with solitary fibrous tumors (SFTs) and is utilized in diagnosing SFTs through nuclear STAT6 protein overexpression. Recent studies expanded the phenotypic spectrum of NAB2::STAT6 rearranged neoplasms, including adamantinoma-like and teratocarcinosarcoma-like phenotypes. We report a case of a NAB2::STAT6 rearranged epithelial tumor exhibiting sebaceous differentiation in the parotid gland.
View Article and Find Full Text PDFArch Dermatol Res
January 2025
Department of Dermatology, Columbia University Irving Medical Center, 161 Ft Washington Ave, 12th Floor, New York, NY, 10032, USA.
Sebaceous carcinoma is a rare cutaneous malignancy of sebaceous glands, but it is up to 25-fold more common in immunosuppressed individuals. In this narrative review, we examine the current literature on the pathogenesis, incidence, risk factors, prognosis, treatment, and surveillance of sebaceous carcinoma in immunosuppression and highlight practical considerations for providers who care for these patients. Increased incidence may be related to decreased immune surveillance, susceptibility to an unknown viral trigger, microsatellite instability, immunosuppressive medications, and unmasking of occult Muir-Torre Syndrome.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!